HIV-1-INFECTION

This early-stage trial tested a new DNA-based HIV vaccine (INO-6160) alone or with a protein booster in 20 healthy adults without HIV. The main goal was to see if the vaccine is safe and whether it triggers antibodies and T-cells against HIV. The study is complete, and results wi…

This study tested a program called SYV (The Voice of Youth) to see if supporting mental health helps young people with HIV take their medication regularly. 690 youth aged 10-24 in Tanzania took part. The goal was to improve viral suppression by addressing mental health challenges…

This completed Phase 4 trial tested the HIV drug Biktarvy in 202 people who were newly diagnosed with HIV and had low CD4 counts (under 200), meaning they started treatment late. Participants received either Biktarvy or a standard three-drug combination. The main goal was to see …

This study tested a new once-daily combination pill (doravirine/islatravir) in 599 adults newly diagnosed with HIV-1 who had never taken HIV medication. The goal was to see if the new pill works as well as a standard three-drug regimen at keeping the virus under control. Results …

This early-stage study tested a new experimental HIV medicine, GS-3242, in 27 people living with HIV-1. The goal was to see if the drug is safe and can lower the amount of virus in the blood over 11 days. Participants had not taken HIV medication for at least 12 weeks before the …

This phase 2a trial tested a new experimental drug called STP0404 (Pirmitegravir) in 25 adults with HIV-1 who had never taken HIV medications before. Participants received either a low, medium, or high dose of STP0404 or a placebo once daily for 10 days. The study measured how we…

This study tested whether the BCG vaccine, normally used to prevent tuberculosis, could reduce the hidden HIV reservoir in people living with HIV who are on antiretroviral therapy. Sixty participants received either a single BCG shot or a placebo. Researchers measured changes in …

This study followed 27 HIV-positive people with kidney failure who received a kidney transplant. All were on a three-drug HIV treatment including Raltegravir. The goal was to see how many had graft rejection within 6 months, using blood tests and kidney biopsies.

This study tested two different once-daily HIV medication combinations in 101 people who had just been infected with HIV-1. The goal was to see which combo better lowered the amount of hidden virus in immune cells after 48 weeks. Both treatments are standard HIV therapies, so thi…

This study tested a two-drug combination of raltegravir and etravirine in 170 adults with HIV who were at least 45 years old and already had the virus well-controlled. Participants switched from a standard three-drug regimen to this simpler two-pill combo. After 96 weeks, over 98…

This study tested a smartphone app called START to help men with HIV who use stimulants like methamphetamine take their medication regularly. The goal was to lower their viral load and improve health. The app provided support and reminders, and the study measured how well it work…

This study looked at 33 adults with well-controlled HIV who switched from a monthly injectable treatment (CAB+RPV) to a daily oral pill (B/F/TAF). The main goal was to check if the switch was safe, especially for those who couldn't or didn't want to continue injections. Over 12 w…

This study tested whether switching from a daily HIV pill (Biktarvy) to a once-weekly combination of two experimental drugs (islatravir and ulonivirine) is safe and tolerable. It involved 161 adults whose HIV was already well-controlled on daily therapy. The goal was to see if a …

This study tested a combination of two lab-made antibodies (VRC07-523LS and CAP256V2LS) and an immune-boosting pill (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy. The goal was to see if the regimen is safe and might help control the virus …

This study tested whether a stronger tuberculosis (TB) treatment could save more lives in people with HIV and very weak immune systems. Over 1,300 hospitalized patients received either the standard TB drugs or an intensified version with higher doses of two key medicines, plus a …

This early-stage study tested a new gene therapy in 2 HIV-positive people with high-risk lymphoma. The therapy involved taking their own stem cells and immune cells, adding a gene to block HIV, and giving them back after chemotherapy. The main goal was to see if the procedure was…

This study tested a combination of two lab-made antibodies, TMB-365 and TMB-380, in 51 adults with HIV whose virus was already controlled by daily oral medication. The goal was to see if switching to these antibody infusions every 8 weeks could keep the virus suppressed safely. R…

This study tested whether Trogarzo, an HIV medication, can be given as a quick 30-second injection into a vein or as a shot into a muscle, instead of the usual 15-minute infusion. Researchers enrolled 43 people, including some with HIV and some healthy volunteers, to check safety…

This study tested a new HIV medication (Biktarvy) taken twice daily in 122 adults who also have drug-sensitive tuberculosis (TB) and are on standard TB treatment. The goal was to see if the new pill can control HIV just as well as the current standard treatment. The study measure…

This pilot study tested a combination of HIV drugs (dolutegravir plus two NRTIs) in 19 HIV-positive people who had received a solid organ transplant (heart, liver, or kidney). The goal was to see how the HIV drugs interact with transplant medications and whether the regimen is sa…

This study looked back at medical records of 800 people with HIV to compare two drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus suppressed over 48 weeks. Participants were adults already on HIV…

This trial tested an injectable drug called PRO 140 (Leronlimab) in 6 people with HIV who had developed resistance to standard medications. The goal was to see if adding PRO 140 to their current failing therapy could reduce the amount of virus in their blood. The study lasted 25 …

This study tested whether taking capsules containing healthy donor stool (fecal microbiota transplantation, or FMT) can reduce gut inflammation in people with HIV who are on antiretroviral therapy (ART) but have a low CD4/CD8 ratio. Twenty participants were randomly assigned to r…

This study tested a resilience-building program called RISE+ in 106 people over 50 living with HIV. Participants watched videos and did activities to improve coping skills, optimism, and social connections. The goal was to see if the program helps them handle daily stress better …

This study looked at 777 people with HIV in Brazil who failed their first treatment with tenofovir, lamivudine, and dolutegravir. Researchers wanted to understand what types of drug resistance and virus subtypes were involved. The goal is to improve treatment choices for people i…

This study looks at why certain immune cells (CD4 and CD8 T cells) remain activated in people with HIV whose viral load has been undetectable on antiretroviral therapy for at least two years. Researchers are investigating whether a common virus called cytomegalovirus (CMV) or an …

This study investigates why the gut immune barrier remains damaged in people with HIV even after successful antiretroviral therapy. Researchers collected blood and intestinal biopsies from 80 participants to measure immune cells and inflammation. The goal is to understand why the…

This study looked at 20 men with HIV who were stable on a common drug combination. Researchers took samples of blood, lymph nodes, rectal tissue, fat, and semen to measure how much of the drugs reached these areas. The goal was to understand why HIV can still hide in some tissues…

This study looked at how a single dose of methamphetamine affects the HIV virus in people who are already on effective HIV treatment. Fourteen HIV-positive adults with no history of meth use took part. The goal was to see if meth causes the virus to become more active and increas…

This study looked at how moderate alcohol use affects inflammation and brain health in people with HIV. Researchers gave controlled amounts of alcohol to 76 healthy volunteers and people with HIV, then used blood tests and brain scans to measure immune and brain changes. The goal…

This study looked at 16 mothers with HIV who chose to breastfeed while taking antiretroviral medication. Researchers measured drug levels in the mothers' blood and breastmilk, and in the babies' blood, to see how much medicine the infants received. The goal was to gather informat…